Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. The company is headquartered in Bethesda, Maryland and currently employs 25 full-time employees. The company went IPO on 2001-12-14. The firm is focused on developing personalized immune therapies for cancer. The company has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The firm's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. The company has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its platform technology, DCVax, is a personalized immune therapy that uses a patient’s own dendritic cells, or DCs, the master cells of the immune system, as the therapeutic agent. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, and others.
Follow-Up Questions
CEO của Northwest Biotherapeutics Inc là ai?
Ms. Linda Powers là Chairperson of the Board của Northwest Biotherapeutics Inc, tham gia công ty từ 2007.
Hiệu suất giá của cổ phiếu NWBO như thế nào?
Giá hiện tại của NWBO là $0.229, đã decreased 0% trong ngày giao dịch cuối cùng.
Chủ đề kinh doanh chính hoặc ngành của Northwest Biotherapeutics Inc là gì?
Northwest Biotherapeutics Inc thuộc ngành Biotechnology và lĩnh vực là Health Care
Vốn hóa thị trường của Northwest Biotherapeutics Inc là bao nhiêu?
Vốn hóa thị trường hiện tại của Northwest Biotherapeutics Inc là $339.4M